California-based OptiScan Biomedical Corp., a monitoring systems developer for hospital intensive care units, has raised $20 million in Series E financing.
OptiScan plans to use the proceeds from the funding for the commercialization of its lead product, the OptiScanner 5000, in the U.S.
Furthermore, the company will also use a portion of the funds to continue the extension of its OptiScanner platform to monitor additional analytes of interest for critically ill patients.
OptiScan Biomedical has raised a total of $150.2 million in over six funding rounds.